Previous close | 585.37 |
Open | 585.37 |
Bid | 592.00 |
Ask | 602.00 |
Strike | 370.00 |
Expiry date | 2025-01-17 |
Day's range | 392.00 - 585.37 |
Contract range | N/A |
Volume | |
Open interest | 3 |
EXEL vs. REGN: Which Stock Is the Better Value Option?
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.